Takeda To Submit NDA For Brentuximab Vedotin In Europe
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical announced Phase II trial results for brentuximab vedotin for patients with hard-to-treat Hodgkin's lymphoma